FDA Determines Regulatory Review Period for INTERCEPT BLOOD SYSTEM FOR PLASMA Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially announced its decision on the regulatory review period for INTERCEPT BLOOD SYSTEM FOR PLASMA, a medical device, in accordance with federal regulations, following a request from the U.S. Patent and Trademark Office (USPTO).